WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, alpha-tubulin acetylation and gamma-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1].
Molecular Weight:
351.40
CAS Number:
[1620054-84-3]
Formula:
C20H21N3O3
Target:
Apoptosis,HDAC,Topoisomerase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
